Investors of Syneos Health Approve a $7 Billion Equity Purchase

Showing appreciation to investors for their involvement in the sale, Syneos President Michelle Keefe said, “We look forward to closing the transaction, further executing on our growth priorities, and driving customer success by delivering fit-for-purpose, integrated solutions that help them bring life-saving therapies to patients.”

By the end of the year, the transaction should be completed, excluding usual closing requirements and governmental clearances. While Syneos would no longer be listed on the Nasdaq, its headquarters will remain in North Carolina.

The business provides pharmaceutical clients with medical and commercial expertise. Over the year, Syneos has introduced two newly established agency companies: Genicos and Spherico.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved